Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1
- PMID: 17200434
- DOI: 10.1161/01.HYP.0000255636.11931.a2
Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1
Abstract
Accumulating evidence suggests that mineralocorticoid receptor blockade effectively reduces proteinuria in hypertensive patients. However, the mechanism of the antiproteinuric effect remains elusive. In this study, we investigated the effects of aldosterone on podocyte, a key player of the glomerular filtration barrier. Uninephrectomized rats were continuously infused with aldosterone and fed a high-salt diet. Aldosterone induced proteinuria progressively, associated with blood pressure elevation. Notably, gene expressions of podocyte-associated molecules nephrin and podocin were markedly decreased in aldosterone-infused rats at 2 weeks, with a gradual decrease thereafter. Immunohistochemical studies and electron microscopy confirmed the podocyte damage. Podocyte injury was accompanied by renal reduced nicotinamide-adenine dinucleotide phosphate oxidase activation, increased oxidative stress, and enhanced expression of aldosterone effector kinase Sgk1. Treatment with eplerenone, a selective aldosterone receptor blocker, almost completely prevented podocyte damage and proteinuria, with normalization of elevated reduced nicotinamide-adenine dinucleotide phosphate oxidase activity. In addition, proteinuria, podocyte damage, and Sgk1 upregulation were significantly alleviated by tempol, a membrane-permeable superoxide dismutase, suggesting the pathogenic role of oxidative stress. Although hydralazine treatment almost normalized blood pressure, it failed to improve proteinuria and podocyte damage. In cultured podocytes with consistent expression of mineralocorticoid receptor, aldosterone stimulated membrane translocation of reduced nicotinamide-adenine dinucleotide phosphate oxidase cytosolic components and oxidative stress generation in podocytes. Furthermore, aldosterone enhanced the expression of Sgk1, which was inhibited by mineralocorticoid receptor antagonist and tempol. In conclusion, podocytes are injured at the early stage in aldosterone-infused rats, resulting in the occurrence of proteinuria. Aldosterone can directly modulate podocyte function, possibly through the induction of oxidative stress and Sgk1.
Similar articles
-
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors.J Am Soc Nephrol. 2006 Dec;17(12):3438-46. doi: 10.1681/ASN.2006080944. Epub 2006 Nov 2. J Am Soc Nephrol. 2006. PMID: 17082236
-
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.Hypertension. 2006 Jun;47(6):1084-93. doi: 10.1161/01.HYP.0000222003.28517.99. Epub 2006 Apr 24. Hypertension. 2006. PMID: 16636193
-
Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production.Nephrol Dial Transplant. 2011 Aug;26(8):2475-84. doi: 10.1093/ndt/gfq750. Epub 2011 Jan 10. Nephrol Dial Transplant. 2011. PMID: 21220752
-
Aldosterone and glomerular podocyte injury.Clin Exp Nephrol. 2008 Aug;12(4):233-242. doi: 10.1007/s10157-008-0034-9. Epub 2008 Mar 5. Clin Exp Nephrol. 2008. PMID: 18317876 Review.
-
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.Clin Exp Nephrol. 2010 Aug;14(4):303-14. doi: 10.1007/s10157-010-0298-8. Epub 2010 Jun 9. Clin Exp Nephrol. 2010. PMID: 20533072 Review.
Cited by
-
Ameliorative Effects of Bredemolic Acid on Markers Associated with Renal Dysfunction in a Diet-Induced Prediabetic Rat Model.Oxid Med Cell Longev. 2020 Jun 22;2020:2978340. doi: 10.1155/2020/2978340. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 32655765 Free PMC article.
-
Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.World J Urol. 2016 Jan;34(1):89-95. doi: 10.1007/s00345-015-1563-y. Epub 2015 May 17. World J Urol. 2016. PMID: 25981400
-
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.Kidney Dis (Basel). 2022 Nov 14;9(1):12-25. doi: 10.1159/000528066. eCollection 2023 Jan. Kidney Dis (Basel). 2022. PMID: 36756081 Free PMC article. Review.
-
Clinical implications of mineralocorticoid receptor overactivation.Clin Kidney J. 2024 Nov 21;18(1):sfae346. doi: 10.1093/ckj/sfae346. eCollection 2025 Jan. Clin Kidney J. 2024. PMID: 39781481 Free PMC article. Review.
-
Aldosterone blockade in chronic kidney disease: can it improve outcome?Curr Opin Nephrol Hypertens. 2010 Sep;19(5):444-9. doi: 10.1097/MNH.0b013e32833ce6d5. Curr Opin Nephrol Hypertens. 2010. PMID: 20625290 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources